Lavie Bio Announces Commercial Expansion of Yalos as Seed-Treatment for Soybean, Following Successful Field Trials
Lavie Bio Announces Commercial Expansion of Yalos as Seed-Treatment for Soybean, Following Successful Field Trials
Lavie Bio intends to commence Yalos sales for soybean in 2025 US spring season
Lavie Bio打算在2025年美國春季開始銷售大豆的Yalos
REHOVOT, Israel, Nov. 12, 2024 /PRNewswire/ -- Lavie Bio Ltd., a leading ag-biologicals company and a subsidiary of Evogene Ltd. (Nasdaq: EVGN) (TASE: EVGN), today announced the commercial expansion of Yalos seed-treatment to soybean, following successful field trials performed in 2024 in the US. Yalos, Lavie Bio's first commercial bio-inoculant product available in the US and Canada, demonstrated yield increase by more than 5% on average, in soybean.
以色列雷霍沃特，2024年11月12日 / PRNewswire/ - 雷啵生物股份有限公司，領先的農業生物公司，evogene有限公司（納斯達克：EVGN）（TASE：EVGN）的子公司，今天宣佈將Yalos種子處理商品化擴展到大豆，此前在美國進行的2024年田間試驗取得成功。Yalos是雷啵生物在美國和加拿大首個商業生物接種產品，大豆產量平均增加了5%以上。
譯文內容由第三人軟體翻譯。